Clinical and histopathological characteristics of prostate cancer in Erbil city/ Iraq

Narin Shakir Mola ahmed; Luqman Rahman Sulaiman

doi:10.15218/zjms.2024.49

Authors

Narin Shakir Mola ahmed Ministry of Health, Erbil, Iraq.
Luqman Rahman Sulaiman Department of Internal Medicine, College of Medicine, Hawler Medical University, Erbil, Iraq.

DOI:

https://doi.org/10.15218/zjms.2024.49

Keywords:

Prostate cancer, Gleason Score, PSA, Erbil city

Abstract

Background and objective: Prostate cancer is the third most common cancer in men in Iraq. We aimed to study the epidemiology, clinical and histopathological characteristics of prostate cancer in Erbil city.

Methods: The research was performed retrospectively at Nanakali Teaching Hospital and the Oncology Department of Rizgary Teaching Hospital in Erbil city, covering the period from 2016 to 2021. Comprising 212 people diagnosed with prostate cancer.

Results: The median age of the patients was 71 years. The proportion of patients who present with urinary tract symptoms, no symptoms and other were 81.6%, 4.7% and 13.7% respectively. Two hundred eight prostate cancer patients with available histopathological data had adenocarcinoma and two patients had neuroendocrine carcinoma and one patient had urothelial cancer. The proportion of patients with high grade tumor, intermediate and low grade were 61%, 29% and 10% respectively. While, the percentage of patients with TPSA level > 20 ng/ml, TPSA >100 ng/ml were 80% and 35% respectively. Furthermore, the proportion of patients with stage IV, III, II and I were 62.7%, 17.9%, 17.9% and 1.4% respectively. And, the percentage of high-risk groups, intermediate and low risk were 90.1%, 8% and 1.9% respectively. After correlation of TPSA with stage of disease and grade of tumor there was statistically positive correlation between them.

Conclusion: Patients diagnosed with prostate cancer in our region are more likely to belong to the high-risk category, exhibiting aggressive disease and advanced stage at the time of diagnosis. Nevertheless, they exhibit comparable demography and epidemiology as shown in the recent international literature about the global population and the Middle East region.

Metrics

Metrics Loading ...

References

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71:209–49. https://doi.org/10.3322/caac.21660

Word Health Organization. Iraq-International Agency for Research on Cancer. Globcan 2020. Available from: https://gco.iarc.fr/today/data/factsheets/populations/368-iraq-fact-sheets.pdf

Perdana NR, Mochtar CA, Umbas R, Hamid ARAH. The Risk Factors of Prostate Cancer and Its Prevention: A Literature Review. Acta Med Indones 2016; 48(3):228–38. PMID: 27840359.

Panigrahi GK, Praharaj PP, Kittaka H, Mridha AR, Black OM, Singh R, et al. Exosome proteomic analyses identify inflammatory phenotype and novel biomarkers in African American prostate cancer patients. Cancer Med 2019; 8:1110–23. https://doi.org/10.1002/cam4.1885

Prostate Cancer Symptoms and Signs. Prostate Cancer Foundation 2022. Available from: https://www.pcf.org/about-prostate-cancer/what-is-prostate-cancer/prostate-cancer-symptoms-signs/

Ried K, Tamanna T, Matthews S, Eng P, Sali A. New Screening Test Improves Detection of Prostate Cancer Using Circulating Tumor Cells and Prostate-Specific Markers. Front Oncol 2020; 10:582. doi: 10.3389/fonc.2020.00582 PMID: 32391268; PMCID: PMC7192049.

Lin CY, Wang SS, Yang CK, Li JR, Chen CS, Hung SC, et al. Genetic polymorphism and carbonic anhydrase 9 expression can predict nodal metastatic prostate cancer risk in patients with prostate-specific antigen levels ≤10 ng/ml at initial biopsy. Urol Oncol 2019; 37(11):814.e9–16. https://doi.org/10.1016/j.urolonc.2019.05.004

Humphrey PA. Histological variants of prostatic carcinoma and their significance. Histopathology 2012; 60(1):59–74. doi: 10.1111/j.1365-2559.2011.04039.x PMID: 22212078.

Faisal FA, Tosoian JJ, Han M, Macura KJ, Pavlovich CP, Lotan TL. Clinical, Pathological and Oncologic Findings of Radical Prostatectomy with Extraprostatic Extension Diagnosed on Preoperative Prostate Biopsy. J Urol 2019; 201(5):937–42. doi: 10.1016/j.juro.2018.10.023 PMID: 30414957.

Pilon D, Ellis L A, Behl A S, Gozalo L, Emond B, Lefebvre P, et al. Assessment of Evidence-Based Standards in the Treatment of Advanced Prostate Cancer in a Community Practice. Urology Practice 2017; 4(3):218–24. https://doi.org/10.1016/j.urpr.2016.06.004

Clarke JM, Armstrong AJ. Novel therapies for the treatment of advanced prostate cancer. Curr Treat Options Oncol 2013; 14(1):109–26. doi: 10.1007/s11864-012-0222-4. PMID: 23322116; PMCID: PMC3591460.

Prostate Cancer - Statistics. Cancer. Net 2022. Available from: https://www.cancer.net/cancer-types/prostate-cancer/statistics

National Comprehensive Cancer Network. Prostate cancer (version 1.2022). Available from: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf

Cao G, Li Y, Wang J, Wu X, Zhang Z, Zhanghuang C, et al. Gleason score, surgical and distant metastasis are associated with cancer-specific survival and overall survival in middle aged high-risk prostate cancer: A population-based study. Front Public Health 2022; 10:1028905. doi: 10.3389/fpubh.2022.1028905. PMID: 36330113; PMCID: PMC9624381.

Brawley OW. Prostate cancer epidemiology in the United States. World J Urol 2012; 30(2):195–200. https://doi.org/10.1007/s00345-012-0824-2

Daher M, Telvizian T, Dagher C, Abdul-Sater Z, Massih SA, Chediak AE, et al. High rates of advanced prostate cancer in the Middle East: Analysis from a tertiary care center. Urol Ann 2021; 13(4):418–23. doi: 10.4103/UA.UA_47_20. PMID: 34759656; PMCID: PMC8525480.

MacKintosh FR, Sprenkle PC, Walter LC, Rawson L, Karnes RJ, Morrell CH, et al. Age and Prostate-Specific Antigen Level Prior to Diagnosis Predict Risk of Death from Prostate Cancer. Front Oncol 2016; 6:157. doi: 10.3389/fonc.2016.00157 PMID: 27446803; PMCID: PMC4923265.

Pettersson A, Robinson D, Garmo H, Holmberg L, Stattin P. Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study. Ann Oncol 2018; 29(2):377–85. doi: 10.1093/annonc/mdx742. PMID: 29161337.

Donnelly DW, Vis LC, Kearney T, Sharp L, Bennett D, Wilding S, et al. Quality of life among symptomatic compared to PSA-detected prostate cancer survivors - results from a UK wide patient-reported outcomes study. BMC Cancer 2019; 19(1):947. doi: 10.1186/s12885-019-6164-5. PMID: 31615476; PMCID: PMC6792209.

Kavita K, Neelam S, Sarita A, Satyendra S, Renu S. “Correlation between Gleason Score of Adenocarcinoma Prostate and Serum PSA Levels in the Western Himalayan Region of India.” Indian Journal of Pathology and Oncology 2020:223–7. https://doi.org/10.18231/j.ijpo.2020.043

Elabbady A, Eid A, Fahmy A, Kotb AF. Pattern of prostate cancer presentation among the Egyptian population: A study in a single tertiary care center. Cent European J Urol 2014; 67(4):351–6. doi: 10.5173/ceju.2014.04.art7. PMID: 25667753; PMCID: PMC4310882.

Carlsson SV, Vickers AJ. Screening for Prostate Cancer. Med Clin North Am 2020; 104(6):1051–62. doi: 10.1016/j.mcna.2020.08.007. PMID: 33099450; PMCID: PMC8287565.

Taha SM, Weng HY, Mohammed MEI, Osman YM, N'dri N, Mohammed SI, et al. Prostate cancer clinical characteristics and outcomes in Central Sudan. Ecancermedicalscience 2020;14:1116. doi: 10.3332/ecancer.2020.1116. PMID: 33209107; PMCID: PMC7652421.

Albasri A, El Siddig A, Hussainy A, Mahrous M, Alhosaini AA, Alhujaily A. “Histopathologic characterization of prostate diseases in Madinah, Saudi Arabia.” Asian Pac J Cancer Prev 2014; 15(10):4175–9. doi: 10.7314/apjcp.2014.15.10.4175. PMID: 24935366.

Youl Lee J, Taniguchi T, Zhang K, Ng CF, Hakim L, Umbas R, et al. Report of the fourth Asian Prostate Cancer (A-CaP) study meeting. JPN J Clin Oncol 2019; 49(6):581–6. doi: 10.1093/jjco/hyz053. PMID: 31141613.

Garg H, Seth A, Kumar R. Raised prostate-specific antigen alone may not be a true predictor in high-risk prostate cancer: A retrospective cohort analysis. Indian J Urol 2022; 38(1):22–8. doi: 10.4103/iju.iju_368_21. PMID: 35136291; PMCID: PMC8796766.

Shah RB, Zhou M. Histologic Variants of Acinar Adenocarcinoma, Ductal Adenocarcinoma, Neuroendocrine Tumors, and Other Carcinomas. In: Prostate Biopsy Interpretation. Springer, Cham; 2019. https://doi.org/10.1007/978-3-030-13601-7_6

Humphrey PA. Histopathology of Prostate Cancer. Cold Spring Harb Perspect Med 2017; 7(10):a030411. doi: 10.1101/cshperspect.a030411. PMID: 28389514; PMCID: PMC5629988.

Alsulihem AA, Al Muaiqel M, Alsunbul A, Jawhar AB, Al Dughaiman A, Bedaiwi KK, et al. “Histopathological diagnoses and patterns in transrectal ultrasound-guided prostatic biopsy series from a large tertiary care center in Saudi Arabia. Urology Annals 2021; 101–4. doi: 10.4103/UA.UA_78_20

Boehm K, Borgmann H, Ebert T, Höfner T, Khaljani E, Schmid M, et al. “Stage and Grade Migration in Prostate Cancer Treated With Radical Prostatectomy in a Large German Multicenter Cohort.” Clin Genitourin Cancer 2021; 19(2):162–6. doi: 10.1016/j.clgc.2020.12.004

Mosillo C, Iacovelli R, Ciccarese C, Fantinel E, Bimbatti D, Brunelli M, et al. De novo metastatic castration sensitive prostate cancer: State of art and future perspectives. Cancer Treat Rev 2018; 70:67-74. doi: 10.1016/j.ctrv.2018.08.005. PMID: 30121492

Kagawa M, Kawakami S, Yamamoto A, Suzuki O, Eguchi H, Okazaki Y, et al. Prevalence and clinicopathological/molecular characteristics of mismatch repair protein-deficient tumours among surgically treated patients with prostate cancer in a Japanese hospital-based population. Jpn J Clin Oncol 2021; 51(4):639–45. https://doi.org/10.1093/jjco/hyaa207

Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 2017; 71(4):618–29. doi: 10.1016/j.eururo.2016.08.003. PMID: 27568654.

McKay RR, Feng FY, Wang AY, Wallis CJD, Moses KA. Recent Advances in the Management of High-Risk Localized Prostate Cancer: Local Therapy, Systemic Therapy, and Biomarkers to Guide Treatment Decisions. Am Soc Clin Oncol Educ Book 2020; 40:1–12. doi: 10.1200/EDBK_279459. PMID: 32412803.

Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, et al. Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options. J Urol 2018; 199(3):683–90. doi: 10.1016/j.juro.2017.11.095. PMID: 29203269.

Xie M, Gao XS, Ma MW, Gu XB, Li HZ, Lyu F, et al. Population-Based Comparison of Different Risk Stratification Systems Among Prostate Cancer Patients. Front Oncol 2021; 11:646073. doi: 10.3389/fonc.2021.646073. PMID: 33928035; PMCID: PMC8076565.

Kibona S, Mbwambo O, Ngowi N, Bright F, Mbwambo J, Mteta A, et al. Correlation Between Bone Metastases and PSA Among Prostate Cancer Patients at Kilimanjaro Christian Medical Centre from June 2018 to May 2019 IJCU 2021; 5(1):47–50. doi: 10.11648/j.ijcu.20210501.20

Lojanapiwat B, Anutrakulchai W, Chongruksut W, Udomphot C. Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice. Prostate Int 2014; 2(3):133–9. doi: 10.12954/PI.14054. PMID: 25325025; PMCID: PMC4186957.